لټون
Developing and implementing a Drug reduce University Diploma for health practitioners in Uruguay: challenges and future directions
In Uruguay, there is a shortage of trained professionals in drug prevention, intervention, and resolution of drug-related issues, particularly among health personnel in domains such as rehabilitation, prevention, schools, communities, and...
ATI Basics: SUD Treatment for Persons in the Justice System
Developing and implementing a Drug reduce University Diploma for health practitioners in Uruguay: challenges and future directions
ATI Basics: Fundamentals of Alternatives to Incarceration (ATI)
Can a "treatment specialist" also be seen as a "prevention specialist" and vice versa?
Pharmacological and Behavioral Treatment of Opioid Use Disorder
Abstract
Objective:
Opioid use disorder (OUD) in the United States has surged, with an estimated 2.5 million needing treatment. The aim of this article is to provide a clinical overview of the key pharmacological and behavioral treatments...
ATI Basics: Why Alternatives to Incarceration (ATI)?
Continental Training of Trainers (ToT) on the CHILD Curriculum and In-Person Training in Egypt
Children's drug use in Africa is a growing concern that requires urgent attention and comprehensive strategies. Understanding the complex factors influencing children's drug use and implementing effective prevention and intervention...
Continental Training of Trainers (ToT) on the CHILD Curriculum and In-Person Training in Egypt
Children's drug use in Africa is a growing concern that requires urgent attention and comprehensive strategies. Understanding the complex factors influencing children's drug use and implementing effective prevention and intervention...
Intervenciones en trastornos por usos de sustancias (TUS): una mirada desde la Psicología y la Neurociencia
Stimulant Use Webinar Series. Part I: About Amphetamine Type Stimulants and Stimulant Use Disorder
Pharmacological management of acute methamphetamine withdrawal
About the webinar:
This seminar provided an overview of Liam’s PhD studies, beginning with a systematic review and meta-analysis of previously researched pharmacological treatments for methamphetamine withdrawal.
It then proposed a novel...
د هغو کسانو په منځ کې چې سرحدی شخصیت بې نظمۍ لری د ځان وژنې د هڅې یا بشپړ خطر لپاره د درملو درملنې مقایسوی اغیزمنتیا
لنډیز
د ځان وژنې اهمیت په هغو کسانو کې چې د سرحدی شخصیت بې نظمۍ (BPD) لری یو مهم کلینیکی اندیښنه ده، مګر د ځان وژنې د خطر په کمولو کې د درملنې اغیزمنتیا نامعلومه ده.
هدف: په سویډن کې د BPD په ناروغانو کې د ځان وژنې د هڅې یا بشپړ کیدو په...
Psychedelics د BDNF ریسیپټر TrkB ته په مستقیم ډول پابند کولو سره پلاستیکیت ته وده ورکوی
چکیده
روانی درمل ګړندی او دوامداره انټی ډیپریشن اغیزې رامینځته کوی او نیوروپلاستی هڅوی چې د کلینیکی پلوه تصویب شوی انډیډیپریټینټونو اغیزو سره ورته وی. موږ پدې وروستیو کې راپور ورکړ چې د درملتونولوژیک پلوه متنوع انټی ډیپریشنینټونه ، پشمول د...
څنګه د الکول څښل د مزمن درد لامل کیږی
یوې ډلې وښودله چې څنګه د الکول مصرف او د الکول وتلو دواړه کولی شی د درد او حساسیت زیاتوالی لامل شی.
د الکول اوږدمهاله مصرف ممکن خلک د دوه مختلف مالیکول میکانیزمونو له لارې درد ته ډیر حساس کړی - یو د الکول مصرف او بل د الکول وتلو له لارې.
...FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
For Immediate Release: May 23, 2023
Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...
La FDA aprueba una nueva opción de tratamiento con buprenorfina para el trastorno por consumo de opioides
Para publicación inmediata: 24 de mayo del 2023
Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó la inyección subcutánea (para uso por debajo de la piel) de Brixadi...
Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review
Abstract
Objective
The crisis of opioid use puts a strain on resources in the United States and worldwide. There are 3 US Food and Drug Administration–approved medications for treatment of opioid use disorder: methadone, buprenorphine...
Focal mu-opioid receptor activation promotes neuroinflammation and microglial activation in the mesocorticolimbic system: Alterations induced by inflammatory pain
Abstract
Microglia participates in the modulation of pain signaling. The activation of microglia is suggested to play an important role in affective disorders that are related to a dysfunction of the mesocorticolimbic system (MCLS) and are...